Sequencing of the Canine Cytochrome P450 CYP2C41 Gene and Genotyping of Its Polymorphic Occurrence in 36 Dog Breeds.

作者: Joachim Geyer , Silke Leiting , Emre Karakus , Clarissa Prinzinger

DOI: 10.3389/FVETS.2021.663175

关键词: GeneticsPharmacogeneticsCytochrome P450GeneGene polymorphismGenotypingAllele frequencyAlleleBiologyFrench bulldog

摘要: Cytochrome P450 (CYP) drug metabolizing enzymes play an important role in efficient metabolism and elimination. Many CYPs are polymorphic and, thereby, can vary between individuals. In the case of canine CYP2C41, gene polymorphism was identified. However, as first available genome sequences all were CYP2C41 negative, this could not be clarified at genomic level. The present study provides exact characterization deletion level presents a PCR-based genotyping method that used for 1,089 individual subjects from 36 different dog breeds. None Bearded Collie, Bernese Mountain, Boxer, Briard, French Bulldog or Irish Wolfhound had their genomes. contrast, Chinese Char-Pei, Siberian Husky, Schapendoes Kangal breeds, allele frequency very high, with values 67, 57, 43, 34%, respectively. Interestingly, site identical negative dogs, positive dogs showed highly homologous sequence domains upstream downstream gene. now routinely future pharmacokinetic studies canines, order to identify genetically-based poor extensive metabolizers. This, together more vitro screening substrates will help determine clinical relevance optimize treatment. Although relative abundance protein liver seems CYP substantially contribute hepatic expressing both alleles when shows higher catalytic activity given than other metabolic enzymes.

参考文章(33)
Joyce A. Goldstein, Joyce Blaisdell, Stephen A. Bai, Isolation of a New Canine Cytochrome P450 cDNA from the Cytochrome P450 2C Subfamily (CYP2C41) and Evidence for Polymorphic Differences in Its Expression Drug Metabolism and Disposition. ,vol. 26, pp. 278- 283 ,(1998)
Katrina L. Mealey, Steve A. Bentjen, John M. Gay, Glenn H. Cantor, Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene Pharmacogenetics. ,vol. 11, pp. 727- 733 ,(2001) , 10.1097/00008571-200111000-00012
Masashi Mise, Seiji Yadera, Michiaki Matsuda, Takanori Hashizume, Satoshi Matsumoto, Yoshiaki Terauchi, Toshihiko Fujii, POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS Drug Metabolism and Disposition. ,vol. 32, pp. 240- 245 ,(2004) , 10.1124/DMD.32.2.240
Marilyn N. Martinez, Leposava Antonovic, Michael Court, Mauro Dacasto, Johanna Fink-Gremmels, Butch Kukanich, Chuck Locuson, Katrina Mealey, Michael J. Myers, Lauren Trepanier, Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics Drug Metabolism Reviews. ,vol. 45, pp. 218- 230 ,(2013) , 10.3109/03602532.2013.765445
B. L. Hay Kraus, D. J. Greenblatt, K. Venkatakrishnan, M. H. Court, Evidence for propofol hydroxylation by cytochrome P4502B11 in canine liver microsomes: breed and gender differences. Xenobiotica. ,vol. 30, pp. 575- 588 ,(2000) , 10.1080/004982500406417
Joyce A. Goldstein, Sonia M. F. de Morais, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics. ,vol. 4, pp. 285- 300 ,(1994) , 10.1097/00008571-199412000-00001
Michael H. Court, Canine cytochrome P-450 pharmacogenetics. Veterinary Clinics of North America-small Animal Practice. ,vol. 43, pp. 1027- 1038 ,(2013) , 10.1016/J.CVSM.2013.05.001
M. J. Graham, A. R. Bell, H. K. Crewe, C. L. Moorcraft, L. Walker, E. F. Whittaker, M. S. Lennard, mRNA and protein expression of dog liver cytochromes P450 in relation to the metabolism of human CYP2C substrates. Xenobiotica. ,vol. 33, pp. 225- 237 ,(2003) , 10.1080/0049825021000048782